Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia

background: the detection of molecular and cytogenetic alterations is important for the diagnosis, prognosis and classification of myeloproliferative neoplasms. objective: the aim of this study was to detect the following mutations: jak2 v617f, jak2 exon 12 and mpl w515k/l, besides chromosomal abnormalities. furthermore, molecular and cytogenetic alterations were correlated with the leukocyte and platelet counts, hemoglobin levels and age in all patients and with the degree of fibrosis in primary myelofibrosis cases. methods: twenty cases of polycythemia vera, 17 of essential thrombocythemia and 21 of primary myelofibrosis were selected in the hematology department of the universidade federal de s？o paulo (unifesp) between february 2008 and december 2009. the jak2 v617f, jak2 exon 12 mutations, mpl w515k and mpl w515l mutations were investigated by real-time pcr and direct sequencing. g-band karyotyping and fluorescence in situ hybridization were used to detect chromosomal abnormalities. results: chromosomal abnormalities were observed only in polycythemia vera (11.8%) and primary myelofibrosis cases (17.6%), without correlation to clinical data. chromosomal abnormalities were not detected by fluorescence in situ hybridization. the jak2 v617f mutation was observed in polycythemia vera (90%), primary myelofibrosis (42.8%) and essential thrombocythemia (47%). patients with jak2 v617f-negative polycythemia vera had lower platelet and leukocyte counts compared to v617f-positive polycythemia vera (p-value = 0.0001 and p-value = 0.023, respectively). jak2 v617f-positive and mpl w515l-positive primary myelofibrosis cases had a higher degree of fibrosis than v617f-negative cases (p-value = 0.022). jak2 exon 12 mutations were not detected in polycythemia vera patients. the mpl w515l mutation was observed in one case of primary myelofibrosis and in one of essential thrombocythemia. the mpl w515k mutation was not found in patients with essential thrombocythemia or primary myel